GLUE
insider transactionsMonte Rosa Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-97.4K
0 buy · 97.4K sell
Net value · 365d
-$1.7M
$0 in · $1.7M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
19
0 buy · 97.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Operating Officer · 10b5-1
$0
2.2K sh
Own +6%
-
Sell·S
Chief Operating Officer · 10b5-1
$43.5K
2.2K sh · $20.00
Own -3%
-
Exercise·M
Chief Operating Officer · 10b5-1
$8.7K
2.2K sh · $3.98
Own +3%
-
Exercise·M
Chief Operating Officer · 10b5-1
$0
2.2K sh
Own +6%
-
Sell·S
Chief Operating Officer · 10b5-1
$41.3K
2.2K sh · $19.00
Own -3%
-
Exercise·M
Chief Operating Officer · 10b5-1
$8.7K
2.2K sh · $3.98
Own +3%
-
Exercise·M
Director
$0
10.0K sh
Own +476%
-
Sell·S
Director
$180.1K
10.0K sh · $18.01
Own -100%
-
Exercise·M
Director
$41.6K
10.0K sh · $4.16
Own New
-
Sell·S
Warmuth Markus KEY
President & CEO
$141.1K
8.0K sh · $17.64
Own -1%
-
Sell·S
Chief Business & Legal Officer
$103.4K
5.8K sh · $17.69
Own -10%
-
Grant·A
Principal Accounting Officer
$0
19.5K sh
Own New
-
Grant·A
Principal Accounting Officer
—
4.3K sh
Own +20%
-
Sell·S
Principal Accounting Officer
$2.5K
139 sh · $17.96
Own -1%
-
Exercise·M
Principal Accounting Officer
$0
536 sh
Own New
-
Exercise·M
Principal Accounting Officer
$7.2K
536 sh · $13.41
Own +2%
-
Sell·S
Principal Accounting Officer
$9.4K
536 sh · $17.50
Own -2%
-
Sell·S
Warmuth Markus KEY
President & CEO · 10b5-1
$98.0K
5.5K sh · $17.92
Own -1%
-
Exercise·M
Principal Accounting Officer
$0
25.2K sh
Own New
-
Sell·S
Principal Accounting Officer
$455.5K
25.2K sh · $18.10
Own -53%
-
Exercise·M
Principal Accounting Officer
$337.4K
25.2K sh · $13.41
Own +111%
-
Sell·S
Chief Medical Officer
$179.2K
9.2K sh · $19.50
Own -12%
-
Sell·S
Warmuth Markus KEY
President & CEO · 10b5-1
$86.2K
3.7K sh · $23.24
Own -1%
-
Sell·S
Warmuth Markus KEY
President & CEO · 10b5-1
$34.6K
1.4K sh · $23.88
Own -0%
-
Sell·S
Warmuth Markus KEY
President & CEO · 10b5-1
$7.6K
309 sh · $24.57
Own -0%
-
Sell·S
Principal Accounting Officer
$15.8K
1.0K sh · $15.17
Own -4%
-
Sell·S
Chief Medical Officer
$47.9K
3.2K sh · $15.17
Own -4%
-
Sell·S
Warmuth Markus KEY
President & CEO
$153.7K
10.1K sh · $15.17
Own -2%
-
Sell·S
Chief Scientific Officer
$47.9K
3.2K sh · $15.17
Own -4%
-
Sell·S
Chief Business & Legal Officer
$47.9K
3.2K sh · $15.17
Own -5%
-
Sell·S
Chief Operating Officer
$39.9K
2.6K sh · $15.17
Own -4%
-
Grant·A
Chief Medical Officer
$0
139.0K sh
Own New
-
Grant·A
Chief Medical Officer
—
31.0K sh
Own +66%
-
Grant·A
Warmuth Markus KEY
President & CEO
$0
406.0K sh
Own New
-
Grant·A
Warmuth Markus KEY
President & CEO
—
90.0K sh
Own +17%
-
Grant·A
Chief Scientific Officer
$0
158.0K sh
Own New
-
Grant·A
Chief Scientific Officer
—
35.0K sh
Own +97%
-
Grant·A
Chief Business & Legal Officer
$0
126.0K sh
Own New
-
Grant·A
Chief Business & Legal Officer
—
28.0K sh
Own +78%
-
Grant·A
Chief Operating Officer
$0
158.0K sh
Own New
-
Grant·A
Chief Operating Officer
—
35.0K sh
Own +117%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Champoux Jennifer 10b5-1 | Exercise M | 2.2K | $0 |
| May 27, 2026 | Champoux Jennifer 10b5-1 | Sell S | 2.2K | $43.5K |
| May 27, 2026 | Champoux Jennifer 10b5-1 | Exercise M | 2.2K | $8.7K |
| May 22, 2026 | Champoux Jennifer 10b5-1 | Exercise M | 2.2K | $0 |
| May 22, 2026 | Champoux Jennifer 10b5-1 | Sell S | 2.2K | $41.3K |
| May 22, 2026 | Champoux Jennifer 10b5-1 | Exercise M | 2.2K | $8.7K |
| May 21, 2026 | Manning Anthony M. | Exercise M | 10.0K | $0 |
| May 21, 2026 | Manning Anthony M. | Sell S | 10.0K | $180.1K |
| May 21, 2026 | Manning Anthony M. | Exercise M | 10.0K | $41.6K |
| Apr 14, 2026 | Warmuth Markus KEY | Sell S | 8.0K | $141.1K |
| Apr 9, 2026 | Nickson Philip | Sell S | 5.8K | $103.4K |
| Apr 6, 2026 | Matthew Bowen | Grant A | 19.5K | $0 |
| Apr 6, 2026 | Matthew Bowen | Grant A | 4.3K | — |
| Mar 4, 2026 | Dunn Edmund | Sell S | 139 | $2.5K |
| Mar 2, 2026 | Dunn Edmund | Exercise M | 536 | $0 |
| Mar 2, 2026 | Dunn Edmund | Exercise M | 536 | $7.2K |
| Mar 2, 2026 | Dunn Edmund | Sell S | 536 | $9.4K |
| Mar 2, 2026 | Warmuth Markus KEY 10b5-1 | Sell S | 5.5K | $98.0K |
| Feb 27, 2026 | Dunn Edmund | Exercise M | 25.2K | $0 |
| Feb 27, 2026 | Dunn Edmund | Sell S | 25.2K | $455.5K |
| Feb 27, 2026 | Dunn Edmund | Exercise M | 25.2K | $337.4K |
| Feb 23, 2026 | Janku Filip | Sell S | 9.2K | $179.2K |
| Jan 7, 2026 | Warmuth Markus KEY 10b5-1 | Sell S | 3.7K | $86.2K |
| Jan 7, 2026 | Warmuth Markus KEY 10b5-1 | Sell S | 1.4K | $34.6K |
| Jan 7, 2026 | Warmuth Markus KEY 10b5-1 | Sell S | 309 | $7.6K |
| Jan 5, 2026 | Dunn Edmund | Sell S | 1.0K | $15.8K |
| Jan 5, 2026 | Janku Filip | Sell S | 3.2K | $47.9K |
| Jan 5, 2026 | Warmuth Markus KEY | Sell S | 10.1K | $153.7K |
| Jan 5, 2026 | Townson Sharon | Sell S | 3.2K | $47.9K |
| Jan 5, 2026 | Nickson Philip | Sell S | 3.2K | $47.9K |
| Jan 5, 2026 | Champoux Jennifer | Sell S | 2.6K | $39.9K |
| Jan 2, 2026 | Janku Filip | Grant A | 139.0K | $0 |
| Jan 2, 2026 | Janku Filip | Grant A | 31.0K | — |
| Jan 2, 2026 | Warmuth Markus KEY | Grant A | 406.0K | $0 |
| Jan 2, 2026 | Warmuth Markus KEY | Grant A | 90.0K | — |
| Jan 2, 2026 | Townson Sharon | Grant A | 158.0K | $0 |
| Jan 2, 2026 | Townson Sharon | Grant A | 35.0K | — |
| Jan 2, 2026 | Nickson Philip | Grant A | 126.0K | $0 |
| Jan 2, 2026 | Nickson Philip | Grant A | 28.0K | — |
| Jan 2, 2026 | Champoux Jennifer | Grant A | 158.0K | $0 |
| Jan 2, 2026 | Champoux Jennifer | Grant A | 35.0K | — |
About GLUE insider trading
This page tracks insider transactions for Monte Rosa Therapeutics, Inc. (GLUE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.